UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
vTv Therapeutics (Nasdaq: VTVT), a late-stage biopharmaceutical company developing cadisegliatin for type 1 diabetes treatment, has announced its participation in two major investor conferences in September 2025.
The company will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 9 for one-on-one investor meetings, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, where management will participate in a fireside chat from 2:35 PM to 3:10 PM EST, along with individual investor meetings.
vTv Therapeutics (Nasdaq: VTVT), azienda biofarmaceutica in fase avanzata che sta sviluppando cadisegliatin per il trattamento del diabete di tipo 1, ha comunicato la sua partecipazione a due importanti conferenze per investitori a settembre 2025.
La società sarà presente al H.C. Wainwright 27th Annual Global Investment Conference il 9 settembre per incontri individuali con investitori, e al Morgan Stanley 23rd Annual Global Healthcare Conference il 10 settembre, dove la direzione parteciperà a una fireside chat dalle 14:35 alle 15:10 EST, oltre a singoli meeting con investitori.
vTv Therapeutics (Nasdaq: VTVT), compañía biofarmacéutica en fase avanzada que desarrolla cadisegliatin para el tratamiento de la diabetes tipo 1, ha anunciado su participación en dos importantes conferencias para inversores en septiembre de 2025.
La empresa asistirá a la H.C. Wainwright 27th Annual Global Investment Conference el 9 de septiembre para reuniones individuales con inversores, y a la Morgan Stanley 23rd Annual Global Healthcare Conference el 10 de septiembre, donde la dirección participará en una fireside chat de 2:35 PM a 3:10 PM EST, además de mantener reuniones individuales con inversores.
vTv Therapeutics (Nasdaq: VTVT), 제1형 당뇨병 치료제 카디세글리틴을 개발 중인 후기 단계 바이오제약사로서 2025년 9월에 열리는 두 건의 주요 투자자 콘퍼런스에 참석한다고 발표했습니다.
회사는 9월 9일 H.C. Wainwright 27th Annual Global Investment Conference에서 투자자와의 일대일 미팅을 진행하고, 9월 10일 Morgan Stanley 23rd Annual Global Healthcare Conference에서는 경영진이 미국 동부시간(EST) 기준 오후 2시 35분부터 3시 10분까지 파이어사이드 채팅에 참여하며 개별 투자자 미팅도 진행할 예정입니다.
vTv Therapeutics (Nasdaq: VTVT), société biopharmaceutique en phase avancée développant le cadisegliatin pour le traitement du diabète de type 1, a annoncé sa participation à deux grandes conférences investisseurs en septembre 2025.
La société assistera à la H.C. Wainwright 27th Annual Global Investment Conference le 9 septembre pour des rencontres individuelles avec des investisseurs, et à la Morgan Stanley 23rd Annual Global Healthcare Conference le 10 septembre, où la direction participera à une fireside chat de 14h35 à 15h10 EST, en plus de réunions individuelles avec des investisseurs.
vTv Therapeutics (Nasdaq: VTVT), ein biopharmazeutisches Unternehmen in der Spätphase, das Cadisegliatin zur Behandlung von Typ-1-Diabetes entwickelt, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird am 9. September an der H.C. Wainwright 27th Annual Global Investment Conference für Einzelgespräche mit Investoren teilnehmen und am 10. September an der Morgan Stanley 23rd Annual Global Healthcare Conference, wo das Management von 14:35 bis 15:10 Uhr EST an einem Fireside Chat teilnehmen wird, sowie an separaten Investorenmeetings.
- None.
- None.
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:
| H.C. Wainwright 27th Annual Global Investment Conference | |
| Date: | Tuesday, September 9, 2025 |
| Format: | 1x1 Investor Meetings Only |
| Morgan Stanley 23rd Annual Global Healthcare Conference | |
| Date: | Wednesday, September 10, 2025 |
| Format: | Fireside Chat Time: 2:35 PM - 3:10 PM EST and 1x1 Investor Meetings |
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
FAQ
When is VTVT presenting at the Morgan Stanley Healthcare Conference 2025?
What conferences is vTv Therapeutics (VTVT) attending in September 2025?
What is vTv Therapeutics' (VTVT) main drug development focus?
What type of meetings will VTVT have at the H.C. Wainwright Conference?
